false000073027200007302722026-05-142026-05-14

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2026

 

 

REPLIGEN CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-14656

04-2729386

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

41 Seyon Street

 

Waltham, Massachusetts

 

02453

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (781) 250-0111

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

RGEN

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders

On May 14, 2026, Repligen Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). As of March 16, 2026, the record date for the 2026 Annual Meeting, 56,399,274 shares of the Company’s common stock were issued and outstanding, of which 54,022,359 shares were represented, in person or by proxy, at the 2026 Annual Meeting, constituting a quorum. At the 2026 Annual Meeting, the Company’s stockholders voted on the following proposals, which are described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 2, 2026:

i.
to elect the nine (9) director nominees identified in the Proxy Statement to the Company’s Board of Directors;
ii.
to consider and ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; and
iii.
to consider and act upon a non-binding, advisory vote to approve the compensation of the Company’s named executive officers.

Each of the director nominees in proposal 1 were duly elected by, and each of proposals 2 and 3 were approved by, the Company’s stockholders at the 2026 Annual Meeting. The following voting results are final:

Proposal 1 - Election of the Board of Directors

Nominee

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

Olivier Loeillot

 

 

51,750,665

 

 

 

116,198

 

 

 

31,383

 

 

 

2,124,113

 

Martin Madaus, D.V.M., Ph.D.

 

 

51,091,036

 

 

 

775,295

 

 

 

31,915

 

 

 

2,124,113

 

Karen A. Dawes

 

 

42,726,647

 

 

 

9,132,553

 

 

 

39,046

 

 

 

2,124,113

 

Nicolas M. Barthelemy

 

 

51,526,602

 

 

 

339,481

 

 

 

32,163

 

 

 

2,124,113

 

Carrie Eglinton Manner

 

 

41,987,697

 

 

 

9,871,020

 

 

 

39,529

 

 

 

2,124,113

 

Konstantin Konstantinov, Ph.D.

 

 

51,137,462

 

 

 

728,874

 

 

 

31,910

 

 

 

2,124,113

 

Rohin Mhatre, Ph.D.

 

 

51,649,920

 

 

 

215,384

 

 

 

32,942

 

 

 

2,124,113

 

Glenn P. Muir

 

 

38,592,456

 

 

 

13,265,484

 

 

 

40,306

 

 

 

2,124,113

 

Margaret A. Pax

 

 

51,011,846

 

 

 

849,103

 

 

 

37,297

 

 

 

2,124,113

 

Proposal 2 - Ratification of the Appointment of Independent Registered Public Accounting Firm

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

53,092,462

 

 

 

900,084

 

 

 

29,813

 

 

 

 

Proposal 3 - Advisory Vote on Compensation of the Named Executive Officers

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

50,333,558

 

 

 

1,513,515

 

 

 

51,173

 

 

 

2,124,113

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

REPLIGEN CORPORATION

 

 

 

 

Date:

May 15, 2026

By:

/s/ Olivier Loeillot

 

 

 

Olivier Loeillot

 

 

 

President and Chief Executive Officer